Journals / Glokom Katarakt / 2017 / Cilt: 12 - Sayı: 3

Phacoemulsifi cation Surgery and Hemorrhagic Complications in Subjects on Anticoagulant and Antiplatelet Treatment

Antikoagülan ve Antiplatelet İlaç Kullanan Bireylerde Fakoemülsifi kasyon Cerrahisi ve Hemorajik Komplikasyonlar

Pages
209–213
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For patients using new generation anticoagulants, we recommend stopping the medication 24 hours before surgery to be continued 24 hours after the end of surgery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: We aimed to evaluate preoperative therapy and complications following phacoemulsifi cation (PE) in subjects using anticoagulant/antiplatelet treatment.Materials and Methods: We included subjects using anticoagulant and/or antiplatelet treatment and who had undergone cataract surgery with PE using a clear corneal incision in the study.
📊
Key Findings & Data:The age, gender, reason for anticoagulant/antiplatelet treatment, preoperative drug strategy and hemorrhagic complications were assessed.Results: The 158 patients (mean age 70.79±7.87 years; min-max 51-92 years) consisted of 80 males and 78 females.
💡
Conclusion & Impact:For patients using new generation anticoagulants, we recommend stopping the medication 24 hours before surgery to be continued 24 hours after the end of surgery.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: We aimed to evaluate preoperative therapy and complications following phacoemulsifi cation (PE) in subjects using anticoagulant/antiplatelet treatment.Materials and Methods: We included subjects using anticoagulant and/or antiplatelet treatment and who had undergone cataract surgery with PE using a clear corneal incision in the study. The age, gender, reason for anticoagulant/antiplatelet treatment, preoperative drug strategy and hemorrhagic complications were assessed.Results: The 158 patients (mean age 70.79±7.87 years; min-max 51-92 years) consisted of 80 males and 78 females. The anticoagulant/antiplatelet treatment consisted of acetylsalicylic acid (ASA) in more than two-thirds (69.62%), followed by clopidogrel (10.75%) and warfarin (9.49%). The treatment was continued before PE in more than 90% of patients taking ASA while most warfarin and clopidogrel users were started on temporary low molecular weight heparin (LMWH) treatment. Subconjunctival hemorrhage developed in 5 patients during surgery (2 patients using ASA, 2 using LMWH following warfarin and 1 with stopped clopidogrel treatment). Anterior chamber hemorrhage developed in 2 patients who were using temporary LMWH following warfarin. No complications were encountered in patients using Dabigatran or Rivaroxaban.Conclusion: PE surgery under topical anesthesia following antiplatelet use is safe. Safe PE can be ensured in warfarin users by temporary use of LMWH keeping the International Normalized Ratio at a therapeutic level. For patients using new generation anticoagulants, we recommend stopping the medication 24 hours before surgery to be continued 24 hours after the end of surgery.

Özet

Amaç: Antikoagülan/antiplatelet kullanan hastalarda fakoemülsifi kasyon (FE) ile katarakt ameliyatı öncesi ilaç planlaması ve gelişen komplikasyonları incelemeyi amaçladık.Gereç ve yöntem: Antikoagülan ve/veya antiplatelet ilaç kullanan, topikal anestezi altında saydam korneal kesi kullanılarak FE ile katarakt ameliyatı yapılmış bireyler çalışmaya dahil edildi. Hastaların yaşı, cinsiyeti, antikoagülan/antiplatelet tedavisi alma nedenleri, ameliyat öncesi bu ilaçlarla ilgili strateji ve hemorajik komplikasyonları incelendi.Bulgular: Toplam 158 hastanın (ortalama yaş 70.79±7.87 yıl/min-max 51-92 yıl) 80'i erkek 78'i kadın idi. Antikoagülan/antiplatelet ilaçların üçte ikisinden fazlasını asetilsalisilik asit (ASA) (%69.62) kullanıcıları oluştururken bunu klopidogrel (%10.75) ve warfarin (%9.49) kullanımının takip ettiği görüldü. ASA tedavisi alanlarda FE cerrahisi öncesi yüzde doksanın üzerinde ilaca devam edilmiş, warfarin ve klopidogrel kullanıcıları ise büyük oranda düşük molekül ağırlıklı heparin (DMAH) ile köprüleme tedavisine geçilmiştir. Ameliyat sırasında toplam 5 hastada (2 ASA, 2 warfarinden DMAH ile köprüleme tedavisine geçilen ve 1 klopidogrel kullanımı durdurulmuş olgularda) subkonjonktival hemoraji izlenmiştir. Ameliyat öncesi warfarin tedavisinden DMAH ile köprüleme tedavisine geçilen 2 hastada ön kamarada hemoraji gelişmiştir. Dabigatran ve Rivaroxaban kullanan hastalarda herhangi bir komplikasyon izlenmemiştir.Sonuç: Antiplatelet kullanımı sürdürülerek topikal anestezi altında yapılan FE cerrahisi güvenlidir. Warfarin kullanıcılarında güvenli bir FE cerrahisi, uluslararası normalize edilmiş oran terapotik düzeyde kalınarak veya DMAH ile köprüleme tedavisi ile sağlanabilir. Yeni nesil direkt antikoagülan kullanan hastalarda cerrahiden 24 saat önce ilacın kesilmesi, cerrahi bitiminden 24 saat sonra tekrar başlanması önerilir.

🔖

Cite This Article

KURT, A., KILIÇ, R. (2017). Phacoemulsifi cation Surgery and Hemorrhagic Complications in Subjects on Anticoagulant and Antiplatelet Treatment. Glokom Katarakt, Cilt: 12 - Sayı: 3, 209–213. https://ajindex.com/articles/177742

References (15)

  1. Casparis H, Lindsley K, Kuo IC, et al. Surgery for cataracts in people with age-related macular degeneration. Cochrane Database Syst Rev 2012; 6: CD006757
  2. Kallio H, Paloheimo M, Maunuksela EL. Haemorrhage and risk factors associated with retrobulbar/peribulbar block: a prospective study in 1383 patients. Br J Anaesth 2000; 85: 708-11
  3. Konstantatos A. Anticoagulation and cataract surgery: a review of the current literature. Anaesth Intensive Care 2001; 29: 11-8
  4. US Preventive Services Task Force: Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404
  5. Aradi D, Komócsi A, Vorobcsuk A, et al. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Haemost 2013; 109: 93-101
  6. Dzeshka MS, Lip GY. Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. Heart Fail Clin 2016; 12: 257-71
  7. Romualdi E, Micieli E, Ageno W, et al. Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review. Thromb Haemost 2009; 101: 290-7
  8. Torn M, Bollen WL, van der Meer FJ, et al. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165: 1527-32
  9. Karadağ B, Ikitimur B, Öngen Z. Perioperative management in patients receiving newer oral anticoagulant and antiaggregant agents. Turk Kardiyol Dern Ars 2012; 40: 548-51
  10. Beving H, Zhao C, Albage A, et al. Abnormally high platelet activity after scontinuation of acetylsalicylic acid treatment. Blood Coagul Fibrinolysis 1996; 7: 80-4
  11. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of non-cardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 35: 1288-94
  12. Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003; 42: 234-40
  13. Rhee SJ, Yun KH, Lee SR, et al. Drug-eluting stent thrombosis during perioperative period. Int Heart J 2008; 49: 135-42
  14. Schouten O, van Domburg RT, Bax JJ, et al. Non-cardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007; 49: 122-4
  15. Kong KL, Khan J. Ophthalmic patients on